...Receives an exclusive license to a TIRC7 program in preclinical development for immunological diseases from GenPat77...

...life sciences. Biotech companies in its portfolio include therapeutic aptamer company Noxxon and autoimmune company GenPat77...

...topoisomerase inhibitor has completed a pilot study in neuroblastoma patients. Further terms were not disclosed. GenPat77 Pharmacogenetics AG...

...GenPat77. The companies will share product development and commercialization responsibilities. Financial terms were not disclosed. GenPat77 Pharmacogenetics AG...

...use its UltiMab Human Antibody Development System to generate antibodies against autoimmune disease targets from GenPat77...

...the 1990s saying that CD28 mediates activation of T cells," noted Nalan Utku, CEO of GenPat77 Pharmacogenetics AG...

...Medarex 11/23/04 Partners to develop two preclinical MEDX antibodies, MDX-1103 and MDX-1333, for autoimmune diseases GenPat77...

...CRTX) Series B $56.0 Y Inotek Series A $20.0 N Iomai Series C $56.0 N GenPat77...

...treatment of many immune diseases, as overall suppression usually makes patients vulnerable to opportunistic infections. GenPat77 Pharmacogenetics AG...
...transmembrane protein that was discovered 10 years ago by Nalan Utku, president and CEO of GenPat77...
...it might serve as a useful early diagnostic and prognostic biomarker, e.g., for transplant rejection." GenPat77...